letrozole has been researched along with Bone Fractures in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial." | 9.14 | Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. ( Campone, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Hawle, H; Láng, I; Mouridsen, H; Nogaret, JM; Paridaens, RJ; Pienkowski, T; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B, 2009) |
| "The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal women with receptor-positive early breast cancer." | 9.14 | Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. ( Coates, AS; Forbes, J; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Regan, MM; Smith, I; Thürlimann, B, 2009) |
| "Patients with early oestrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer treated with letrozole from February 2001 to September 2009 were reviewed." | 7.77 | Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. ( Balakrishnan, A; Ravichandran, D, 2011) |
| "The incidence of bone fractures, observed more often in the letrozole group, did not differ by age." | 6.73 | Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. ( Castiglione-Gertsch, M; Chirgwin, JH; Coates, AS; Colleoni, M; Crivellari, D; Del Mastro, L; Forbes, JF; Gelber, RD; Gladieff, L; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rabaglio, M; Smith, IE; Sun, Z; Thürlimann, B, 2008) |
| "To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial." | 5.14 | Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. ( Campone, M; Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Forbes, JF; Gelber, RD; Goldhirsch, A; Hawle, H; Láng, I; Mouridsen, H; Nogaret, JM; Paridaens, RJ; Pienkowski, T; Price, KN; Rabaglio, M; Smith, I; Sun, Z; Thürlimann, B, 2009) |
| "The aromatase inhibitor letrozole, as compared with tamoxifen, improves disease-free survival among postmenopausal women with receptor-positive early breast cancer." | 5.14 | Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. ( Coates, AS; Forbes, J; Gelber, RD; Giobbie-Hurder, A; Goldhirsch, A; Mauriac, L; Mouridsen, H; Paridaens, R; Price, KN; Regan, MM; Smith, I; Thürlimann, B, 2009) |
| " A meta-analysis revealed an advantage for AIs over tamoxifen in the monotherapy setting for recurrence but not breast cancer mortality, and an advantage in both of these parameters for switching to an AI after several years of tamoxifen." | 4.89 | Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors. ( Ingle, JN, 2013) |
| "Patients with early oestrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer treated with letrozole from February 2001 to September 2009 were reviewed." | 3.77 | Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy. ( Balakrishnan, A; Ravichandran, D, 2011) |
| "The incidence of bone fractures, observed more often in the letrozole group, did not differ by age." | 2.73 | Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. ( Castiglione-Gertsch, M; Chirgwin, JH; Coates, AS; Colleoni, M; Crivellari, D; Del Mastro, L; Forbes, JF; Gelber, RD; Gladieff, L; Goldhirsch, A; Láng, I; Mauriac, L; Mouridsen, H; Paridaens, RJ; Price, KN; Rabaglio, M; Smith, IE; Sun, Z; Thürlimann, B, 2008) |
| "Bone loss may be a potential side effect of implementing aromatase inhibitors in the adjuvant setting." | 2.43 | Bone safety of aromatase inhibitors versus tamoxifen. ( Lønning, PE, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ingle, JN | 1 |
| Rabaglio, M | 2 |
| Sun, Z | 2 |
| Price, KN | 3 |
| Castiglione-Gertsch, M | 2 |
| Hawle, H | 1 |
| Thürlimann, B | 3 |
| Mouridsen, H | 3 |
| Campone, M | 1 |
| Forbes, JF | 2 |
| Paridaens, RJ | 2 |
| Colleoni, M | 2 |
| Pienkowski, T | 1 |
| Nogaret, JM | 1 |
| Láng, I | 2 |
| Smith, I | 2 |
| Gelber, RD | 3 |
| Goldhirsch, A | 3 |
| Coates, AS | 3 |
| Giobbie-Hurder, A | 1 |
| Paridaens, R | 1 |
| Mauriac, L | 2 |
| Forbes, J | 1 |
| Regan, MM | 1 |
| Balakrishnan, A | 1 |
| Ravichandran, D | 1 |
| Lønning, PE | 1 |
| Berruti, A | 1 |
| Tucci, M | 1 |
| Mosca, A | 1 |
| Vana, F | 1 |
| Ardine, M | 1 |
| Dogliotti, L | 1 |
| Angeli, A | 1 |
| Bertoldo, F | 1 |
| Crivellari, D | 1 |
| Del Mastro, L | 1 |
| Gladieff, L | 1 |
| Smith, IE | 1 |
| Chirgwin, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205] | Phase 3 | 8,028 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for letrozole and Bone Fractures
| Article | Year |
|---|---|
Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemothera | 2013 |
Bone safety of aromatase inhibitors versus tamoxifen.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; | 2006 |
3 trials available for letrozole and Bone Fractures
| Article | Year |
|---|---|
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Fractures, Bone; Humans; | 2009 |
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Dis | 2009 |
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; | 2008 |
2 other studies available for letrozole and Bone Fractures
| Article | Year |
|---|---|
Early operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Female; Frac | 2011 |
Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, | 2007 |